Clinical Trial Update: CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC [Phase 2]

View source ↗

Summary

Phase 2 study evaluating CAN-2409 plus a prodrug with standard immune checkpoint inhibitor therapy for stage III/IV non-small cell lung cancer is currently acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CAN-2409

Snippet

Sponsor: Candel Therapeutics, Inc. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING